Drug Type CAR-NK |
Synonyms AntiCD22 chimeric antigen receptor NK cells Allife Medical Science and Technology |
Target |
Action inhibitors |
Mechanism CD22 inhibitors(CD22 inhibitors), Gene transference(Gene transference), Natural killer cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-cell lymphoma refractory | Phase 1 | - | 01 Mar 2019 |





